Impact of preoperative complement-dependent cytotoxicity crossmatch on postoperative outcomes in kidney transplant recipients: A retrospective analysis [PDF]
Journal of International Medical ResearchObjectives The aim of the present study was to compare the differences in clinical outcomes within 6 months postoperatively between a complement-dependent cytotoxicity
Chonghe Xu +4 more
doaj +3 more sources
A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity [PDF]
Medicina, 2022 Background and objectives: The ABO antibody (Ab) titration tests are used in monitoring in ABO-incompatible (ABOi) solid organ transplantation (SOT). However, currently developed ABO Ab tests show Ab binding reactions. This study attempted to measure ABO
Hee-Jeong Youk +9 more
doaj +4 more sources
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells [PDF]
Cancer Biology & TherapyMultiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement ...
Hongjie Wang +5 more
doaj +4 more sources
Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein [PDF]
Frontiers in Neuroscience, 2023 BackgroundThe autoantibody to myelin oligodendrocyte glycoprotein (MOG), a component of the central nervous system myelin, has been identified in a subset of demyelinating diseases.
Kuniko Kohyama +5 more
doaj +2 more sources
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity [PDF]
Nature Communications, 2023 The success of HER2-targeted cancer therapy is limited by treatment resistance. Here, the authors engineer an anti-HER2 biparatopic antibody with multiple mechanisms of action including induction of HER2 clustering to trigger complement dependent ...
Nina E. Weisser +38 more
doaj +2 more sources
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro [PDF]
Scientific ReportsComplement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab.
Harrison D. Collier-Bain +13 more
doaj +2 more sources
Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies [PDF]
Frontiers in ImmunologyAntibody-mediated complement-dependent cytotoxicity (CDC) on malignant cells is regulated by several complement control proteins, including the inhibitory complement factor H (fH).
Lena Prantl +13 more
doaj +2 more sources
Red cell antibodies resulting in false-positive complement-dependent cytotoxicity cross-match: A unique case [PDF]
Asian Journal of Transfusion Science, 2021 A false-positive complement-dependent cytotoxicity cross-match (CDC XM) has a negative impact in donor selection process obliterating healthy, donor compatible population.
Rajesh B Sawant +3 more
doaj +2 more sources
Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis [PDF]
JCI Insight, 2022 Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action (MOA)
Li-Chung Tsao +12 more
doaj +2 more sources
FHR4‐based immunoconjugates direct complement‐dependent cytotoxicity and phagocytosis towards HER2‐positive cancer cells [PDF]
Molecular Oncology, 2019 Directing selective complement activation towards tumour cells is an attractive strategy to promote their elimination. In the present work, we have generated heteromultimeric immunoconjugates that selectively activate the complement alternative pathway ...
Carole Seguin‐Devaux +8 more
doaj +2 more sources